LOOMIS SAYLES & CO L P - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
LOOMIS SAYLES & CO L P ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$49,763
-22.8%
1,096,354
-4.5%
0.08%
-18.3%
Q2 2023$64,445
+23.2%
1,147,929
-0.8%
0.10%
+14.3%
Q1 2023$52,323
+8.3%
1,156,810
-2.7%
0.09%
-6.2%
Q4 2022$48,305
-99.9%
1,188,321
-4.6%
0.10%
-41.2%
Q3 2022$81,374,000
-4.1%
1,245,199
-10.8%
0.16%
+5.1%
Q2 2022$84,850,000
+4.7%
1,396,258
+8.2%
0.16%
+45.4%
Q1 2022$81,030,000
-18.8%
1,290,905
-1.9%
0.11%
-10.7%
Q4 2021$99,736,000
-3.8%
1,316,123
+42.1%
0.12%
-4.7%
Q3 2021$103,638,000
-29.5%
925,914
+1.9%
0.13%
-28.7%
Q2 2021$147,101,000908,6520.18%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2023
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders